Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($) $ in Millions			3 Months Ended			9 Months Ended
	Jul. 01, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenues			$ 3,362.7	$ 2,936.2		$ 9,682.9	$ 8,758.5
Sanofi Collaboration Agreement, Antibody
Disaggregation of Revenue [Line Items]
Percentage share of profits to reimburse collaborating party						10.00%
Percentage of share of profits used to reimburse collaborating party for trial costs	20.00%	10.00%
Sanofi Collaboration Agreement, Antibody | Sales Milestone Three
Disaggregation of Revenue [Line Items]
Levels of twelve-month sales at which sales milestone payments would be received					$ 2,000.0
Period for achieving sales target for milestone payment, rolling basis					12 months
Revenues					$ 50.0
Sanofi Collaboration Agreement, Antibody | Sales Milestone Five
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, variable consideration amount			50.0			$ 50.0
Levels of twelve-month sales at which sales milestone payments would be received			$ 3,000.0
Period for achieving sales target for milestone payment, rolling basis			12 months
Sanofi Collaboration Agreement, Antibody | Minimum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party						80.00%
Percentage share of profits to reimburse collaborating party						30.00%
Sanofi Collaboration Agreement, Antibody | Maximum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party						100.00%
Percentage share of profits to reimburse collaborating party						50.00%